Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 3/20 | 0.62 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572128 | 0.91 | GRIA4 (0.54) | GRIA4GRIA1SMN1; SMN2CA12CA1 | |
| SCHEMBL6575364 | 0.90 | PTGS2 (0.57) | GRIA4SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL6565144 | 0.87 | GRIA4 (0.77) | GRIA4GRIA1SMN1; SMN2CA12CA1 | |
| SCHEMBL6573022 | 0.84 | GRIA4 (0.47) | GRIA4SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL6574096 | 0.84 | GRIA4 (0.47) | GRIA4SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL6763745 | 0.83 | GRIA4 (0.48) | GRIA4SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL6765787 | 0.83 | GRIA4 (0.46) | GRIA4SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL6763716 | 0.82 | KDM4E (0.46) | GRIA4ALDH1A1PTGS2 | |
| SCHEMBL6563388 | 0.81 | GRIA4 (0.69) | GRIA4GRIA1SMN1; SMN2CA12CA1 | |
| SCHEMBL5877603 | 0.79 | GRIA4 (0.67) | GRIA4GRIA1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | GRIA4 17/4885GRIA1 9/4885SMN1; SMN2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.